Trademark Dispute Over Semaglutide Drugs: Implications for Pharmaceutical IPR in India

Indian Express - Explained · 29 Mar 2026 · 2 min read
Prelims · Polity Mains · GS2 Polity and constitution High relevance

Novo Nordisk sued Dr Reddy's Laboratories for trademark infringement over semaglutide drugs, highlighting critical issues in pharmaceutical intellectual property rights and consumer safety in India.

Key points

Novo Nordisk filed a lawsuit against Dr Reddy's Laboratories (DRL) at Delhi High Court, alleging trademark infringement of its semaglutide drug 'Ozempic' by DRL's 'Olymviq'.

DRL conceded to maintain status quo on manufacturing or market release of 'Olymviq', indicating the legal pressure from Novo Nordisk's claims.

The dispute centers on deceptive similarity in drug names, with Novo Nordisk arguing that 'Olymviq' phonetically mimics 'Ozempic', potentially causing consumer confusion.

[GS2-Polity] The case references the Cadila Healthcare Ltd vs. Cadila Pharmaceuticals Ltd (2001) Supreme Court judgment, which established stricter standards for trademark similarity in drugs due to potential health risks.

The Supreme Court's Cadila ruling emphasized that drugs require a lower threshold for deceptive similarity due to India's diverse linguistic and urban-rural divides, prioritizing consumer safety.

Section 13 of the Trademarks Act permits drug names derived from International Non-Proprietary Names (INN) but prohibits deceptive similarity, as seen in the 2022 Delhi HC case of Sun Pharma vs. Hetero Healthcare.

[GS3-Economy] The case underscores the tension between multinational pharma companies protecting patents and Indian generics leveraging expired patents, impacting India's $50 billion pharmaceutical industry.

Novo Nordisk's aggressive litigation reflects its reliance on semaglutide drugs like Ozempic and WeGovy, which contribute significantly to its global revenue amid patent expiry concerns.

Way Forward: India should strengthen its IPR dispute resolution mechanism, establish clearer guidelines for phonetic similarity in drug names, and enhance consumer awareness to prevent confusion in pharmaceutical products.

Key terms

Cadila Healthcare Ltd vs. Cadila Pharmaceuticals Ltd (2001)

A landmark Supreme Court case that established stringent criteria for assessing deceptive similarity in drug trademarks. The ruling emphasized that even slight phonetic resemblance could be harmful, given India's diverse population and healthcare infrastructure, setting a precedent for pharmaceutical IPR cases.

Semaglutide

A glucagon-like peptide-1 (GLP-1) receptor agonist used to treat type-2 diabetes and obesity. Drugs like Ozempic and WeGovy, developed by Novo Nordisk, have become blockbuster products, leading to high-stakes patent and trademark disputes as generics enter the market post-patent expiry.

Deceptive Similarity

A legal doctrine under trademark law where two marks are so similar that they may confuse consumers about the origin of goods or services. In pharmaceuticals, the Supreme Court's Cadila judgment (2001) set a lower threshold for similarity due to potential health risks, making it a critical consideration for drug naming in India.

International Non-Proprietary Names (INN)

Globally recognized generic names for pharmaceutical substances, designated by the WHO to ensure uniformity. Under Section 13 of India's Trademarks Act, INNs cannot be monopolized, but derived names must avoid deceptive similarity to protect consumer safety and prevent trademark infringement.